M
Marion Flipo
Researcher at Pasteur Institute
Publications - 41
Citations - 1083
Marion Flipo is an academic researcher from Pasteur Institute. The author has contributed to research in topics: Mycobacterium tuberculosis & Chemistry. The author has an hindex of 16, co-authored 32 publications receiving 893 citations. Previous affiliations of Marion Flipo include university of lille & Ferring Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Tuberculosis: the drug development pipeline at a glance.
Baptiste Villemagne,Céline Crauste,Marion Flipo,Alain R. Baulard,Benoit Deprez,Nicolas Willand +5 more
TL;DR: The pipeline of potential new treatments has been fulfilled with several compounds in clinical trials or preclinical development with promising activities against sensitive and resistant Mycobacterium tuberculosis strains.
Journal ArticleDOI
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
Nicolas Blondiaux,Martin Moune,Matthieu Desroses,Matthieu Desroses,Rosangela Frita,Marion Flipo,Vanessa Mathys,Karine Soetaert,Mehdi Kiass,Vincent Delorme,Vincent Delorme,Kamel Djaout,Vincent Trebosc,Christian Kemmer,René Wintjens,Alexandre Wohlkonig,Rudy Antoine,Ludovic Huot,David Hot,Mireia Coscolla,Mireia Coscolla,Julia Feldmann,Julia Feldmann,Sebastien Gagneux,Sebastien Gagneux,Camille Locht,Priscille Brodin,Marc Gitzinger,Benoit Deprez,Nicolas Willand,Alain R. Baulard +30 more
TL;DR: The first-of-its-kind molecule, named SMARt-420 (Small Molecule Aborting Resistance), not only fully reverses ethionamide-acquired resistance and clears ethion chloride-resistant infection in mice, it also increases the basal sensitivity of bacteria to ethionamide.
Journal ArticleDOI
Hydroxamates: Relationships between Structure and Plasma Stability
Marion Flipo,Julie Charton,Akila Hocine,Sandrine Dassonneville,Benoit Deprez,Rebecca Deprez-Poulain +5 more
TL;DR: This work performs the first and preliminary study on structure-plasma stability for hydroxamates and defines some structural rules to predict or improve the plasma stability in the preclinical stage.
Journal ArticleDOI
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
Marion Flipo,Matthieu Desroses,Nathalie Lecat-Guillet,Bertrand Dirié,Xavier Carette,Florence Leroux,Catherine Piveteau,Fatma Demirkaya,Zoé Lens,Zoé Lens,Prakash Rucktooa,Prakash Rucktooa,Vincent Villeret,Vincent Villeret,Thierry Christophe,Hee Kyoung Jeon,Camille Locht,Priscille Brodin,Benoit Deprez,Alain R. Baulard,Nicolas Willand +20 more
TL;DR: An extensive structure-activity relationships study with 58 thiophen-2-yl-1,2,4-oxadiazoles as inhibitors of EthR, a transcriptional regulator controling ethionamide bioactivation in Mycobacterium tuberculosis is reported.
Journal ArticleDOI
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
Joana Costa-Gouveia,Elisabetta Pancani,Samuel Jouny,Arnaud Machelart,Vincent Delorme,Giuseppina Salzano,Raffaella Iantomasi,Catherine Piveteau,Christophe J. Queval,Ok-Ryul Song,Marion Flipo,Benoit Deprez,Jean-Paul Saint-André,José Hureaux,Laleh Majlessi,Nicolas Willand,Alain R. Baulard,Priscille Brodin,Ruxandra Gref +18 more
TL;DR: This study paves the way for a future use of pCD NPs for the pulmonary delivery of the [ETH:Booster] pair in TB chemotherapy, overcoming the bottlenecks inherent to the strong tendency of ETH to crystallize and the limited water solubility of this Booster.